Related Experiment Video
Updated: Nov 11, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
Why are immune adverse events so common with checkpoint inhibitor therapy?
Taras Lyubchenko1, Donald Y M Leung2, Elena Goleva2
1Department of Pediatrics, National Jewish Health, Denver, Colorado; Department of Biological Sciences, University of Denver, Colorado.
No abstract available in PubMed .
More Related Videos
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
06:07Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
Published on: February 5, 2020
Related Concept Videos
Tumor Immunotherapy
Allergic Drug Reactions
Cell-mediated Immune Responses
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Inhibition of Cdk Activity
Immunodeficiency Diseases
There are three main causes of immunodeficiency...